The results suggest the inhibition of CD40L is safe and well tolerated and results in a dose-dependent reduction in a broad spectrum of T cell and myeloid associated pro-inflammatory signaling pathways in adults with ALS. Here, CD40LG is linked to amyotrophic lateral sclerosis.